Cargando…
Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study
The purpose of this study is to monitor specific anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) IgG and IgM antibody production in patients with severe forms of coronavirus disease 2019 (COVID-19) using various commercially available quantitative and qualitative tests. The se...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446649/ https://www.ncbi.nlm.nih.gov/pubmed/34539635 http://dx.doi.org/10.3389/fimmu.2021.705441 |
_version_ | 1784568926523359232 |
---|---|
author | Al-Mughales, Jamil A. Al-Mughales, Tareq J. Saadah, Omar I. |
author_facet | Al-Mughales, Jamil A. Al-Mughales, Tareq J. Saadah, Omar I. |
author_sort | Al-Mughales, Jamil A. |
collection | PubMed |
description | The purpose of this study is to monitor specific anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) IgG and IgM antibody production in patients with severe forms of coronavirus disease 2019 (COVID-19) using various commercially available quantitative and qualitative tests. The sera of 23 confirmed COVID-19 patients were processed for anti-SARS-CoV-2 IgG and IgM detection. Three different immunoassays, viz. Abbott Architect(®) SARS-CoV-2 IgG assay, and two quantitative tests, ANSH(®) SARS-CoV-2 and AESKULISA(®) SARS-CoV-2 Nucleocapsid Protein (NP), were performed and the results pooled, from diagnosis to serum collection. Seroconversion rates were computed for all 3 assays, and possible correlations were tested using the Pearson correlation coefficient and Cohen’s kappa coefficient. Overall, 70 combinations of qualitative and quantitative IgG and IgM results were pooled and analyzed. In the early phase (0-4 days after diagnosis), in all tests, IgG seroconversion rates were 43%-61%, and increased in all tests gradually to 100% after 15 days. The Pearson correlation coefficient showed a strong positive relationship between the qualitative IgG test results and both quantitative IgG tests. IgM detection was inconsistent, with maximal concentrations and seroconversion rates between 10-15 days after diagnosis and slight-to-fair agreement between the two quantitative immunoassays. There was no significant association between mortality with IgG or IgM seroconversion or concentrations. Patients with severe COVID-19 develop an early, robust anti-SARS-CoV-2 specific humoral immune response involving IgG immunoglobulins. Further comparative studies are warranted to analyze the value of serological testing in predicting the severity of COVID-19 and detecting prior exposure. |
format | Online Article Text |
id | pubmed-8446649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84466492021-09-18 Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study Al-Mughales, Jamil A. Al-Mughales, Tareq J. Saadah, Omar I. Front Immunol Immunology The purpose of this study is to monitor specific anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) IgG and IgM antibody production in patients with severe forms of coronavirus disease 2019 (COVID-19) using various commercially available quantitative and qualitative tests. The sera of 23 confirmed COVID-19 patients were processed for anti-SARS-CoV-2 IgG and IgM detection. Three different immunoassays, viz. Abbott Architect(®) SARS-CoV-2 IgG assay, and two quantitative tests, ANSH(®) SARS-CoV-2 and AESKULISA(®) SARS-CoV-2 Nucleocapsid Protein (NP), were performed and the results pooled, from diagnosis to serum collection. Seroconversion rates were computed for all 3 assays, and possible correlations were tested using the Pearson correlation coefficient and Cohen’s kappa coefficient. Overall, 70 combinations of qualitative and quantitative IgG and IgM results were pooled and analyzed. In the early phase (0-4 days after diagnosis), in all tests, IgG seroconversion rates were 43%-61%, and increased in all tests gradually to 100% after 15 days. The Pearson correlation coefficient showed a strong positive relationship between the qualitative IgG test results and both quantitative IgG tests. IgM detection was inconsistent, with maximal concentrations and seroconversion rates between 10-15 days after diagnosis and slight-to-fair agreement between the two quantitative immunoassays. There was no significant association between mortality with IgG or IgM seroconversion or concentrations. Patients with severe COVID-19 develop an early, robust anti-SARS-CoV-2 specific humoral immune response involving IgG immunoglobulins. Further comparative studies are warranted to analyze the value of serological testing in predicting the severity of COVID-19 and detecting prior exposure. Frontiers Media S.A. 2021-09-03 /pmc/articles/PMC8446649/ /pubmed/34539635 http://dx.doi.org/10.3389/fimmu.2021.705441 Text en Copyright © 2021 Al-Mughales, Al-Mughales and Saadah https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Al-Mughales, Jamil A. Al-Mughales, Tareq J. Saadah, Omar I. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study |
title | Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study |
title_full | Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study |
title_fullStr | Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study |
title_full_unstemmed | Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study |
title_short | Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study |
title_sort | monitoring specific igm and igg production among severe covid-19 patients using qualitative and quantitative immunodiagnostic assays: a retrospective cohort study |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446649/ https://www.ncbi.nlm.nih.gov/pubmed/34539635 http://dx.doi.org/10.3389/fimmu.2021.705441 |
work_keys_str_mv | AT almughalesjamila monitoringspecificigmandiggproductionamongseverecovid19patientsusingqualitativeandquantitativeimmunodiagnosticassaysaretrospectivecohortstudy AT almughalestareqj monitoringspecificigmandiggproductionamongseverecovid19patientsusingqualitativeandquantitativeimmunodiagnosticassaysaretrospectivecohortstudy AT saadahomari monitoringspecificigmandiggproductionamongseverecovid19patientsusingqualitativeandquantitativeimmunodiagnosticassaysaretrospectivecohortstudy |